Aspirin and NSAIDs for breast cancer chemoprevention
| Autor: | Eugenia Yiannakopoulou |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Drug
Cancer Research Reduced risk Epidemiology Thromboxane medicine.drug_class media_common.quotation_subject Breast Neoplasms Prostacyclin Breast cancer medicine Humans skin and connective tissue diseases media_common Aspirin business.industry Anti-Inflammatory Agents Non-Steroidal Public Health Environmental and Occupational Health Prognosis medicine.disease digestive system diseases Oncology Estrogen Cancer research Female business Tamoxifen medicine.drug |
| Zdroj: | European Journal of Cancer Prevention. 24:416-421 |
| ISSN: | 0959-8278 |
| Popis: | Novel treatment strategies are needed for breast cancer chemoprevention. Tamoxifen is the only drug approved for the chemoprevention of estrogen receptor-positive breast cancer. However, to date, no treatment exists for the chemoprevention of estrogen receptor-negative breast cancer. NSAID use is associated with a reduced risk of breast cancer. However, the biological mechanisms underlying the effect of NSAID on breast cancer are not well defined. NSAIDs inhibit cyclooxygenases, thus preventing the formation of prostaglandins, prostacyclin, and thromboxane. NSAIDs also exert other biological effects, including generation of reactive oxygen species and inhibition of nuclear factor-κB-mediated signals. This review synthesizes the evidence on the COX-2-independent mechanisms of action of aspirin, salicylates, and other NSAIDs on breast cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|